Interictal osmophobia is associated with longer migraine disease duration
- PMID: 35840888
- PMCID: PMC9284850
- DOI: 10.1186/s10194-022-01451-7
Interictal osmophobia is associated with longer migraine disease duration
Abstract
Background: Sensitization to sensory stimuli is an essential feature of migraine attacks. The relationship between the clinical course of migraine and increased sensitivity to olfactory stimuli has been little studied so far.
Methods: We analyzed the frequency and quality of osmophobia depending on the phase of migraine in patients with episodic and chronic migraine treated in an tertiary headache center with regard to gender, age, medical history and migraine disability assessment score (MIDAS). Standardized diagnostic questions were used for the assessment of osmophobia.
Results: In our cross-sectional investigation (n = 113), 38.1% of the patients showed an increased preictal hypersensitivity to odors, whereas 61.9% described ictal and 31.9% interictal hypersensitivity to odors, odor-triggered migraine was described in 30.1%. Median migraine disease duration has been statistically significantly longer in patients who suffered from interictal hypersensitivity to odors (28.5 years vs. 20 years; p = 0.012). There was a significant correlation between interictal hypersensitivity and higher age (54.50 vs. 45; p = 0.015). Patients with higher migraine disability in MIDAS experienced more frequently preictal and interictal olfactory sensitization and odor triggered migraine attacks.
Conclusions: In patients with longer migraine disease duration and higher migraine-related impairment, osmophobia was more frequently observed. These results might support the hypothesis of increasing sensitization with increasing burden of migraine.
Keywords: MIDAS; Migraine; Migraine disorders; Migraine headache; Osmophobia; Sensitization.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that there is no conflict of interest.
Figures


Similar articles
-
Olfactory symptoms reported by migraineurs with and without auras.Headache. 2016 Nov;56(10):1608-1616. doi: 10.1111/head.12973. Epub 2016 Oct 25. Headache. 2016. PMID: 27779326
-
Osmophobia and Odor-Triggered Headaches in Children and Adolescents: Prevalence, Associated Factors, and Importance in the Diagnosis of Migraine.Headache. 2020 May;60(5):954-966. doi: 10.1111/head.13806. Epub 2020 Apr 15. Headache. 2020. PMID: 32293736
-
A prospective study on osmophobia in migraine versus tension-type headache in a large series of attacks.Cephalalgia. 2020 Apr;40(4):337-346. doi: 10.1177/0333102419877661. Epub 2019 Sep 19. Cephalalgia. 2020. PMID: 31537108
-
A lost track in ICHD 3 beta: A comprehensive review on osmophobia.Cephalalgia. 2018 Feb;38(2):340-352. doi: 10.1177/0333102416678390. Epub 2016 Nov 16. Cephalalgia. 2018. PMID: 27919021
-
The not so hidden impact of interictal burden in migraine: A narrative review.Front Neurol. 2022 Nov 3;13:1032103. doi: 10.3389/fneur.2022.1032103. eCollection 2022. Front Neurol. 2022. PMID: 36408525 Free PMC article. Review.
Cited by
-
Association of the insulin resistance marker triglyceride glucose index with migraine: results of a cross-sectional and prospective cohort study.J Oral Facial Pain Headache. 2025 Mar;39(1):165-175. doi: 10.22514/jofph.2025.017. Epub 2025 Mar 12. J Oral Facial Pain Headache. 2025. PMID: 40129435 Free PMC article.
-
Aura and osmophobia are associated with the IL1A -889C > T (rs1800587) variant in migraine.Arq Neuropsiquiatr. 2024 Oct;82(10):1-7. doi: 10.1055/s-0044-1791200. Epub 2024 Nov 6. Arq Neuropsiquiatr. 2024. PMID: 39505006 Free PMC article.
-
Validation of an 8-item self-administered questionnaire for assessing migraine-related sensory hypersensitivities (MHQ-8).J Headache Pain. 2025 May 26;26(1):128. doi: 10.1186/s10194-025-02067-3. J Headache Pain. 2025. PMID: 40414872 Free PMC article.
-
Evaluating the Frequency of Osmophobia in Tension-Type Headache: A Comparative Study on Migraine.Cureus. 2024 Aug 10;16(8):e66558. doi: 10.7759/cureus.66558. eCollection 2024 Aug. Cureus. 2024. PMID: 39252709 Free PMC article.
-
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine.Neurol Int. 2023 Feb 13;15(1):273-284. doi: 10.3390/neurolint15010017. Neurol Int. 2023. PMID: 36810472 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical